Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Platinum-based chemotherapy in recurrent high-grade glioma patients: retrospective study.

Roci E, Cakani B, Brace G, Bushati T, Rroji A, Petrela M, Kaloshi G.

Med Arch. 2014;68(2):140-3.

2.

Carboplatin chemotherapy in patients with recurrent high-grade glioma.

Murray LJ, Bridgewater CH, Levy D.

Clin Oncol (R Coll Radiol). 2011 Feb;23(1):55-61. doi: 10.1016/j.clon.2010.09.007. Epub 2010 Oct 16.

PMID:
20952169
3.
4.

"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.

Galldiks N, Berhorn T, Blau T, Dunkl V, Fink GR, Schroeter M.

J Neurooncol. 2013 Apr;112(2):209-15. doi: 10.1007/s11060-013-1048-z. Epub 2013 Jan 9.

PMID:
23299464
5.

3D conformal radiotherapy and cisplatin for recurrent malignant glioma.

VanderSpek L, Fisher B, Bauman G, Macdonald D.

Can J Neurol Sci. 2008 Mar;35(1):57-64.

PMID:
18380278
6.

Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study.

Hassler MR, Ackerl M, Flechl B, Sax C, Wöhrer A, Widhalm G, Dieckmann K, Hainfellner J, Preusser M, Marosi C.

Anticancer Drugs. 2014 Jul;25(6):723-8. doi: 10.1097/CAD.0000000000000077.

PMID:
24441743
8.

Single agent carboplatin for pediatric low-grade glioma: A retrospective analysis shows equivalent efficacy to multiagent chemotherapy.

Dodgshun AJ, Maixner WJ, Heath JA, Sullivan MJ, Hansford JR.

Int J Cancer. 2016 Jan 15;138(2):481-8. doi: 10.1002/ijc.29711. Epub 2015 Aug 13.

9.

Temozolomide in the treatment of recurrent malignant glioma.

Chang SM, Theodosopoulos P, Lamborn K, Malec M, Rabbitt J, Page M, Prados MD.

Cancer. 2004 Feb 1;100(3):605-11.

10.

A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.

Tang P, Roldan G, Brasher PM, Fulton D, Roa W, Murtha A, Cairncross JG, Forsyth PA.

J Neurooncol. 2006 Jul;78(3):311-6. Epub 2006 May 19.

PMID:
16710748
11.

Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma. RMP-7 European Study Group.

Gregor A, Lind M, Newman H, Grant R, Hadley DM, Barton T, Osborn C.

J Neurooncol. 1999 Sep;44(2):137-45.

PMID:
10619497
12.

Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.

Duerinck J, Du Four S, Sander W, Van Binst AM, Everaert H, Michotte A, Hau P, Neyns B.

Anticancer Res. 2015 Oct;35(10):5551-7.

PMID:
26408725
13.

Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma.

Wiestler B, Radbruch A, Osswald M, Combs SE, Jungk C, Winkler F, Bendszus M, Unterberg A, Platten M, Wick W, Wick A.

J Neurooncol. 2014 Mar;117(1):85-92. doi: 10.1007/s11060-013-1356-3. Epub 2014 Jan 24.

PMID:
24458956
14.

Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience.

Lafay-Cousin L, Sung L, Carret AS, Hukin J, Wilson B, Johnston DL, Zelcer S, Silva M, Odame I, Mpofu C, Strother D, Bouffet E.

Cancer. 2008 Feb 15;112(4):892-9.

15.

Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.

Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, Hukin J, Bartels U, Foreman N, Kellie S, Hilden J, Etzl M, Wilson B, Stephens D, Tabori U, Baruchel S.

J Clin Oncol. 2012 Apr 20;30(12):1358-63. doi: 10.1200/JCO.2011.34.5843. Epub 2012 Mar 5.

PMID:
22393086
16.

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.

Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6. Lancet Oncol. 2015 Feb;16(2):e55.

PMID:
25481791
17.

Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.

Brandes AA, Ermani M, Basso U, Amistà P, Berti F, Scienza R, Rotilio A, Pinna G, Gardiman M, Monfardini S.

Ann Oncol. 2001 Feb;12(2):255-7.

PMID:
11300334
18.

Optimal chemotherapy treatment for women with recurrent ovarian cancer.

Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P.

Curr Oncol. 2007 Oct;14(5):195-208.

19.

Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.

Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, Sardell S, Traish D, Gonsalves A, Wilkins P, Westbury C.

Ann Oncol. 2003 Dec;14(12):1715-21.

PMID:
14630674
20.

Cystemustine in recurrent high grade glioma.

Durando X, Thivat E, Roché H, Bay JO, Lemaire JJ, Verrelle P, Chazal J, Curé H, Chollet P.

J Neurooncol. 2006 Aug;79(1):33-7. Epub 2006 Mar 31. Erratum in: J Neurooncol. 2006 Aug;79(1):39. Lentz, MA [removed].

PMID:
16575534

Supplemental Content

Support Center